Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3774-3780

  Feijen, Elizabeth A M ^a   Leisenring, Wendy M ^b   Stratton, Kayla L ^b   Ness, Kirsten K ^c   Van Der Pal, Helena J H ^a   Caron, Huib N ^a   Armstrong, Gregory T ^c   Green, Daniel M ^c   Hudson, Melissa M ^c   Oeffinger, Kevin C ^d   Robison, Leslie L ^c   Stovall, Marilyn ^e   Kremer, Leontien C M ^a   Chow, Eric J ^b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTOXIN;

ADOLESCENT; ADULT; ARTICLE; CANADA; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DOSE EQUIVALENCE RATIO; DOSE RESPONSE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; NORTH AMERICA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; THORAX RADIOGRAPHY; UNITED STATES; CHEMICALLY INDUCED; COMPARATIVE STUDY; INFANT; NEOPLASMS; ODDS RATIO; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; SURVIVOR; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTOXINS; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DOXORUBICIN; FEMALE; HEART FAILURE; HUMANS; INFANT; MALE; NEOPLASMS; ODDS RATIO; SURVIVORS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84947445525     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.5187     Document Type: Article

References (38)

1. Robison LL, Hudson MM: Survivors of childhood and adolescent cancer: Life-long risks and responsibilities. Nat Rev Cancer 14:61-70, 2014
2. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
3. Van der Pal HJ, van Dalen EC, van Delden E, et al: High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30:1429-1437, 2012
4. Blanco JG, Sun CL, Landier W, et al: Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J Clin Oncol 30:1415-1421, 2012
5. Chow EJ, Chen Y, Kremer LC, et al: Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 33:394-402, 2015
6. Lipshultz S, Lipsitz SR, Mone SM, et al: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
7. Sieswerda E, Postma A, van Dalen EC, et al: The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol 23:2191-2198, 2012
8. Landier W, Bhatia S, Eshelman DA, et al: Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and nursing discipline. J Clin Oncol 22:4979-4990, 2004
9. Armenian SH, Hudson MM, Mulder RL, et al: Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16: e123-e136, 2015
10. Le Deley MC, Leblanc T, Shamsaldin A, et al: Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol 21:1074-1081, 2003
11. Andolina JR, Dilley K: Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors. J Pediatr Hematol Oncol 32:411-415, 2010
12. Abosoudah I, Greenberg ML, Ness KK, et al: Echocardiographic surveillance for asymptomatic lateonset anthracycline cardiomyopathy in childhood cancer survivors. Pediatr Blood Cancer 57:467-472, 2011
13. Bu'lock FA, Mott MG, Oakhill A, et al: Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study. Pediatr Cardiol 20:252-263, 1999
14. Creutzig U, Diekamp S, Zimmermann M, et al: Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 48:651-662, 2007
15. Godoy LY, Fukushige J, Igarashi H, et al: Anthracycline-induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn 39:188-193, 1997
16. Liang DC, Chan TT, Lin KH, et al: Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 20:136-141, 2006
17. Kang M, Kim KI, Song Y, et al: Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients. J Chemotherapy 24:292-296, 2012
18. Keefe DL: Anthracycline-induced cardiomyopathy. Semin Oncol 28:2-7, 2001
19. van Dalen EC, Michiels EM, Caron HN, et al: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 5:CD005006, 2010
20. Sieswerda E, Mulder RL, van Dijk IW, et al: The EKZ/AMC childhood cancer survivor cohort: Methodology, clinical characteristics, and data availability. J Cancer Surviv 7:439-454, 2013
21. Green DM, Grigoriev YA, Nan B, et al: Congestive heart failure after treatment for Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 19:1926-1934, 2001
22. Hudson MM, Ness KK, Nolan VG, et al: Prospective medical assessment of adults surviving childhood cancer: Study design, cohort characteristics, and feasibility of the St Jude Lifetime Cohort study. Pediatr Blood Cancer 56:825-836, 2011
23. Robison LL, Armstrong GT, Boice JD, et al: The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27:2308-2318, 2009
24. Leisenring W, Mertens AC, Armstrong GT, et al: Pediatric cancer survivorship research: Experience of the Childhood Cancer Survivor Study. J Clin Oncol 27:2319-2327, 2009
25. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Bethesda, MD, National Cancer Institute, 2010
26. Prentice RL: A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73:1-11, 1986
27. Barlow WE, Ichikawa L, Rosner D, et al: Analysis of case-cohort designs. J Clin Epidemiol 52:1165-1172, 1999
28. Akaike H: A new look at the statistical model identification. IEEE T Automat Contr 19:716-723, 1974
29. Kaspers GJ, Veerman AJ, Pieters R, et al: In vitro cytoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 8:24-29, 1994
30. Schwartz HS, Grindey GB: Adriamycin and daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 3:1837-1844, 1973
31. Yates J, Glidewell O, Wiernik P, et al: Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 60:454-462, 1982
32. Buckley JD, Lampkin BC, Nesbit ME, et al: Remission induction in children with acute nonlymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: A report from the Children's Cancer Study Group. Med Pediatr Oncol 17:382-390, 1989
33. Schrappe M, Reiter A, Zimmermann M, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALLBFM study group from 1981 to 1995. Leukemia 14:2205-2222, 2000
34. von Hoff DD, Rozencweig M, Layard M, et al: Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases. Am J Med 62:200-208, 1977
35. von Hoff DD, Layard M, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Arch Intern Med 91:710-717, 1979
36. van der Pal HJ, van Dalen EC, Hauptmann M, et al: Cardiac function in 5-year survivors of childhood cancer. Arch Intern Med 170:1247-1255, 2010
37. Armstrong GT, Kawashima T, Leisenring W, et al: Aging and risk of severe, disabling, lifethreatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 32:1218-1227, 2014
38. Armstrong GT, Oeffinger KC, Chen Y, et al: Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31:3673-3680, 2013